Kazia Therapeutics Achieves 86% Tumor Reduction in Triple-Negative Breast Cancer Case

Kazia Therapeutics Reports Significant Tumor Regression in Expanded Access Case for Triple-Negative Breast Cancer

Kazia Therapeutics Limited, an Australian oncology-focused drug development firm, announces a significant breakthrough in its ongoing fight against triple-negative breast cancer (TNBC) through an expanded access case involving a 40-year-old female patient. Initially diagnosed in April 2023, this patient underwent a rigorous treatment regimen that included neoadjuvant chemotherapy and immunotherapy. Following a bilateral mastectomy six weeks later, pathology reports indicated no residual cancer. However, two years post-surgery, she faced a resurgence of the disease, manifesting as metastatic tumors in her bones and lungs. Under a single-patient expanded-access protocol, the patient received a combination of immunotherapy, chemotherapy, and Kazia's investigational drug, paxalisib.

Remarkably, treatment with paxalisib yielded an 86% reduction in overall tumor burden within just three weeks, as revealed by imaging studies. This outcome not only demonstrates the potential of paxalisib in managing advanced TNBC but also highlights the alignment with the patient profiles and treatment strategies currently being evaluated in Kazia's Phase 1b study. This ongoing clinical trial seeks to assess the efficacy of paxalisib in conjunction with Keytruda® (pembrolizumab) and standard chemotherapy, further solidifying Kazia's commitment to advancing therapies for patients facing aggressive forms of breast cancer.

Dr. John Friend, CEO of Kazia Therapeutics, expresses optimism regarding the substantial tumor regression observed in this case, which reinforces the company's dedication to its Phase 1b trial. The trial is structured to evaluate the safety and preliminary anti-tumor activity of paxalisib while also investigating translational biomarkers linked to circulating tumor cell dynamics. As an investigational inhibitor of the PI3K/Akt/mTOR pathway, paxalisib is being developed not only for TNBC but also for various other cancer types, positioning Kazia Therapeutics at the forefront of innovative cancer treatment.

In addition to the promising results from the expanded access case, Kazia Therapeutics continues to focus on its broader clinical development strategy. The company seeks to leverage its findings to enhance understanding of tumor dynamics and improve therapeutic outcomes for patients battling advanced solid tumors. The ongoing commitment to research and development underscores Kazia's role in the evolving landscape of oncology, where novel treatment options are crucial for improving patient prognosis.

Kazia Therapeutics stands poised to make significant contributions to cancer treatment protocols, especially for those with limited therapeutic options. The recent positive results from the expanded access case mark a pivotal step in the company's mission to develop effective therapies for complex malignancies like triple-negative breast cancer.